Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27–40.

CAS  Article  Google Scholar 

Kleinewietfeld M, Hafler DA. Regulatory T cells in autoimmune Neuroinflammation. Immunol Rev. 2014;259(1):231–44.

CAS  Article  Google Scholar 

Melbye P, Olsson A, Hansen TH, Søndergaard HB, Bang OA. Short-chain fatty acids and gut microbiota in multiple sclerosis. Acta Neurol Scand. 2019;139(3):208–19.

Article  Google Scholar 

Robinson AP, Harp CT, Noronha A, Miller SD. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol. 2014;122:173–89.

Article  Google Scholar 

Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479(7374):538–41. https://www.nature.com/articles/nature10554.pdf.

Chen T, Noto D, Hoshino Y, Mizuno M, Miyake S. Butyrate suppresses demyelination and enhances remyelination. J Neuroinflammation. 2019;16(1):165.

Article  Google Scholar 

Luu M, Pautz S, Kohl V, Singh R, Romero R, Lucas S, et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nat Commun; 2019;10(1):1–12.

Duscha A, Gisevius B, Hirschberg S, Yissachar N, Stangl GI, Eilers E, et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell. 2020;180(6):1067-1080.e16.

CAS  Article  Google Scholar 

Park J, Goergen CJ, HogenEsch H, Kim CH. Chronically elevated levels of short-chain fatty acids induce T cell-mediated ureteritis and hydronephrosis. J Immunol. 2016;196(5):2388–400.

CAS  Article  Google Scholar 

Luu M, Visekruna A. Short-chain fatty acids: bacterial messengers modulating the immunometabolism of T cells. Eur J Immunol. 2019;49(6):842–8. https://doi.org/10.1002/eji.201848009.

CAS  Article  PubMed  Google Scholar 

Koh A, de Vadder F, Kovatcheva-Datchary P, Backhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332–45.

CAS  Article  Google Scholar 

Haase S, Haghikia A, Wilck N, Müller DN, Linker RA. Impacts of microbiome metabolites on immune regulation and autoimmunity. Immunology. 2018;154(2):230–8.

CAS  Article  Google Scholar 

Hirschberg S, Gisevius B, Duscha A, Haghikia A. Implications of diet and the gut microbiome in neuroinflammatory and neurodegenerative diseases. Int J Mol Sci 2019; 20(12).

Zeng Q, Junli G, Liu X, Chen C, Sun X, Li H, et al. Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis. Neurochem Int. 2019;129:104468.

CAS  Article  Google Scholar 

Park J, Wang Q, Wu Q, Mao-Draayer Y, Kim CH. Bidirectional regulatory potentials of short-chain fatty acids and their G-protein-coupled receptors in autoimmune neuroinflammation. Sci Rep. 2019;9(1):1–13.

Google Scholar 

Ayling RM, Kok K. Fecal calprotectin. Adv Clin Chem. 2018;87:161–90.

CAS  Article  Google Scholar 

Schwiertz A, Spiegel J, Dillmann U, Grundmann D, Bürmann J, Faßbender K, et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Parkinsonism Relat Disord. 2018;50:104–7.

Article  Google Scholar 

Mulak A, Koszewicz M, Panek-Jeziorna M, Koziorowska-Gawron E, Budrewicz S. Fecal calprotectin as a marker of the gut immune system activation is elevated in parkinson’s disease. Front Neurosci. 2019;13:992.

Article  Google Scholar 

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.

Article  Google Scholar 

Díaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: an update. Mult Scler Relat Disord. 2019;30:215–24.

Article  Google Scholar 

Deutsche Gesellschaft für Neurologie (DGN) e.V. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis Optica Spektrum und MOG-IgG-assoziierte Erkrankungen (cited 2021 Feb 5). https://dgn.org/wp-content/uploads/2020/09/200902_MS-LL_Hauptteil_Konsultationsfassung_KKNMS_202008_final.pdf.

Fenu G, Lorefice L, Frau F, Coghe GC, Marrosu MG, Cocco E. Induction and escalation therapies in multiple sclerosis. Antiinflamm Antiallergy Agents Med Chem. 2015;14(1):26–34.

CAS  Article  Google Scholar 

Multiple Sklerose e.V. Qualitätshandbuch MS/NMOSD: Empfehlungen zur Therapie der Multiplen Sklerose / Neuromyelitis-optica-Spektrum-Erkrankungen für Ärzte. Kompetenznetz Multiple Sklerose (cited 2021 Feb 16); 2020. https://www.kompetenznetz-multiplesklerose.de/wp-content/uploads/2021/01/KKN_2004_WEB_medikamentenhandbuch.pdf.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.

CAS  Article  Google Scholar 

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” J Psychiatr Res. 1975;12(3):189–98.

CAS  Article  Google Scholar 

Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.

CAS  Article  Google Scholar 

Beck AT, Ward CH, Mendelsohn M, Mock J, Erbaugh J. An inventory for measuring depression. Arch General Psychiatry. 1961;4:561–71.

CAS  Article  Google Scholar 

Unger MM, Spiegel J, Dillmann K-U, Grundmann D, Philippeit H, Bürmann J, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66–72.

Article  Google Scholar 

Berg-Hansen P, Vandvik B, Fagerhol M, Holmøy T. Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis. J Neuroimmunol. 2009;216(1–2):98–102.

CAS  Article  Google Scholar 

Nelson SM, Nguyen TM, McDonald JW, MacDonald JK. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;8:CD006097.

PubMed  Google Scholar 

Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7:12015.

CAS  Article  Google Scholar 

Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS ONE. 2015;10(9):e0137429.

Article  Google Scholar 

Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484.

CAS  Article  Google Scholar 

Rizzetto L, Fava F, Tuohy KM, Selmi C. Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex. J Autoimmun. 2018;92:12–34.

CAS  Article  Google Scholar 

Jakobsdottir G, Bjerregaard JH, Skovbjerg H, Nyman M. Fasting serum concentration of short-chain fatty acids in subjects with microscopic colitis and celiac disease: no difference compared with controls, but between genders. Scand J Gastroenterol. 2013;48(6):696–701.

CAS  Article  Google Scholar 

Chen Z, Wu Y, Shrestha R, Gao Z, Zhao Y, Miura Y, et al. Determination of total, free and esterified short-chain fatty acid in human serum by liquid chromatography-mass spectrometry. Ann Clin Biochem. 2019;56(2):190–7.

CAS  Article  Google Scholar